SN
SNOA.US Sonoma Pharmaceuticals Inc
- Market cap
- USD 4.29M
- P/E
- -
- P/B
- 0.84x
- ROE
- -12.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.
Is SNOA.US undervalued?
Graham numberThe Graham number of Sonoma Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sonoma Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Sonoma Pharmaceuticals Inc yet.
Sonoma Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sonoma Pharmaceuticals Inc
Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. It offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatm…
Full company profileSonoma Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Sonoma Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 12.8M | 16.7M | 19.0M | 17.9M | 18.6M | 12.6M | 13.3M | 12.7M | 14.3M | 19.5M | 27.2M |
| Gross Profit | 5.67M | 7.31M | 8.88M | 8.12M | 6.56M | 3.99M | 4.48M | 4.75M | 5.47M | 7.42M | 10.8M |
| Operating Income | -13.0M | -14.2M | -11.3M | -7.39M | -3.45M | -5.89M | -4.57M | -4.70M | -3.71M | -2.46M | 500K |
| EBITDA | -12.7M | -13.7M | -10.9M | -3.22M | -3.22M | -5.22M | -5.06M | -4.86M | -2.77M | -2.32M | 168K |
| Net Income | 9.27M | -14.3M | -11.8M | -3.31M | -3.95M | -5.09M | -5.15M | -4.84M | -3.46M | -3.18M | -792K |
| EPS | 198 | -285 | -128 | -22 | -20 | -19 | -15 | -5.32 | -2.79 | -1.89 | -0.16 |
| Balance Sheet | |||||||||||
| Total Assets | 25.5M | 19.2M | 14.4M | 14.6M | 15.0M | 18.8M | 16.2M | 14.7M | 13.7M | 14.0M | 17.1M |
| Total Liabilities | 4.03M | 3.88M | 3.96M | 8.94M | 9.62M | 10.1M | 8.25M | 8.60M | 9.28M | 10.9M | 10.5M |
| Shareholders' Equity | 21.4M | 15.3M | 10.5M | 5.62M | 5.36M | 8.70M | 7.98M | 6.14M | 4.41M | 3.10M | 6.61M |
| Cash & Short-term Investments | 17.5M | 10.1M | 3.69M | 3.69M | 4.22M | 7.40M | 3.82M | 3.13M | 5.37M | 2.40M | 4.61M |
| Total Debt | 410K | 553K | 475K | 850K | 2.68M | 1.37M | 849K | 608K | 305K | 842K | 602K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -8.17M | -12.4M | -11.7M | -4.59M | -3.38M | -4.25M | -6.15M | -2.40M | -88.0K | -3.93M | -2.77M |
| Capital Expenditure | 394K | 187K | 100K | 206K | 179K | 137K | 269K | 17.0K | 80.0K | 192K | 88.0K |
| Free Cash Flow | -8.56M | -12.6M | -11.8M | -4.80M | -3.56M | -4.39M | -6.42M | -2.42M | -168K | -4.13M | -2.86M |
| Ratios | |||||||||||
| ROE | 43.3% | -93.5% | -112.5% | -58.8% | -73.7% | -58.5% | -64.6% | -78.8% | -78.4% | -102.6% | -12.0% |
| ROA | 36.4% | -74.6% | -81.7% | -22.7% | -26.4% | -27.0% | -31.7% | -32.8% | -25.2% | -22.7% | -4.6% |
| Net Profit Margin | 72.3% | -86.0% | -62.2% | -18.5% | -21.2% | -40.3% | -38.8% | -38.0% | -24.2% | -16.3% | -2.9% |
| Debt to Equity | 0.02x | 0.04x | 0.05x | 0.15x | 0.50x | 0.16x | 0.11x | 0.10x | 0.07x | 0.27x | 0.09x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Sonoma Pharmaceuticals Inc dividends
Sonoma Pharmaceuticals Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:20 on Aug 30, 2024.
Who owns Sonoma Pharmaceuticals Inc
- Insiders 0.39%
- Institutions 6.47%
- Public & others 93.14%
- Shares outstanding 5.06M
- Free float 5.04M
Top funds holding SNOA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 49.5K | 0.98% | +138.22% | Sep 2026 |
| Fidelity Total Market Index | 2.53K | 0.05% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 2.31K | 0.05% | 0.00% | Sep 2026 |
Top institutions holding SNOA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Renaissance Technologies Corp | 77.4K | 1.53% | +91.26% | Sep 2026 |
| Geode Capital Management, LLC | 26.8K | 0.53% | +34.33% | Jun 2026 |
| Vanguard Capital Management, LLC | 18.8K | 0.37% | 0.00% | Jun 2026 |
| Mckinley Carter Wealth Services Inc | 11.2K | 0.22% | 0.00% | Sep 2026 |
| UBS Group AG | 7.81K | 0.15% | +130,033.33% | Jun 2026 |
| Global Retirement Partners, LLC. | 2.55K | 0.05% | +230.05% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 2.00K | 0.04% | -0.20% | Jun 2026 |
| Advisor Group Holdings, Inc. | 500.00 | 0.01% | 0.00% | Jun 2026 |
| Barclays PLC | 459.00 | 0.01% | 0.00% | Jun 2026 |
| BlackRock Inc | 113.00 | 0.00% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 100.00 | 0.00% | 0.00% | Jun 2026 |
| HARBOUR INVESTMENTS, INC. | 15.00 | 0.00% | 0.00% | Jun 2026 |
| Quaker Wealth Management, LLC | 3.00 | 0.00% | 0.00% | Jun 2026 |
| Danske Bank A/S. | 1.00 | 0.00% | 0.00% | Jun 2026 |
| DRW Securities, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Tower Research Capital LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Caitong International Asset Management Co., Limited. | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Citigroup Inc | 0.00 | 0.00% | -100.00% | Jun 2026 |
| U.S. Bancorp | 0.00 | 0.00% | -100.00% | Jun 2026 |
| JPMorgan Chase & Co | 0.00 | 0.00% | -100.00% | Jun 2026 |
Sonoma Pharmaceuticals Inc company profile
- Company name
- Sonoma Pharmaceuticals Inc
- Ticker
- SNOA.US
- Exchange
- USA Stocks
- Listed since
- Jan 25, 2007
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 10
- Fiscal year end
- March
- Address
- 5445 Conestoga Court, Boulder, CO, United States, 80301
- Phone
- 800 759 9305
- Website
- sonomapharma.com
About Sonoma Pharmaceuticals Inc
Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. It offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription and over-the-counter product used to relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and Pediacyn, an atopic dermatitis hydrogel. The company also provides Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a range of pathogens; Ocucyn eyelid and eyelash cleanser; Ocudox for eye care; Sinudox for nasal irrigation; Microdacyn60 oral care solution to treat mouth and throat infections; and Podiacyn, a foot care product. In addition, it offers MicrocynAH, an HOCl-based solution used to relieve common symptoms of hot spots, scratches, skin rashes, post-surgical sites, and irritated animal skin; MicrocynVS, an animal care product; Nanocyn, a hospital-grade disinfectant; Acuicyn, a solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns, a disinfectant; and Endocyn, a root canal irrigation solution. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.
Sonoma Pharmaceuticals Inc management
3- Ms. Amy M. Trombly Esq., J.D.CEO, President & Director · born 1968
- Mr. Jerome J. Dvonch CPAChief Financial Officer · born 1968
- Mr. Arturo AngelSenior Vice President of Regulatory, Quality & Product Development